Merck (NYSE:MRK) is approaching phase 2 data for Winrevair in pulmonary hypertension. Results will focus on the 6 minute walk ...

Sept 2 (Reuters) - Merck's (MRK.N), opens new tab oral drug met the main goal of reducing bad cholesterol in a late-stage trial, it said on Tuesday, marking a second win for the drug since June. The ...

Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial failures for the ...

A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...

Cancer drug dealmaking is heating up around promising candidates with the potential to top Merck by going after two targets versus the one addressed by the pharmaceutical giant’s blockbuster ...

Merck headquarters in Rahway, NJ. RAHWAY, N.J. – Compared to its lackluster second quarter performance, Merck rallied somewhat in the third quarter of 2025. Revenue and earnings exceeded 2024’s third ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be valued at more than $2 billion as the German company seeks to bolster its drug ...